Gustavo A. Rosario Benitez

Array ( [id] => 9908976 [patent_doc_number] => 20150064176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION' [patent_app_type] => utility [patent_app_number] => 14/459656 [patent_app_country] => US [patent_app_date] => 2014-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 69 [patent_no_of_words] => 95109 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14459656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11191567 [patent_doc_number] => 09422368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-23 [patent_title] => 'Humanized anti-human NKG2A monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 14/449346 [patent_app_country] => US [patent_app_date] => 2014-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 31573 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14449346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806547 [patent_doc_number] => 20160152705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON' [patent_app_type] => utility [patent_app_number] => 14/905506 [patent_app_country] => US [patent_app_date] => 2014-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13997 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14905506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11611496 [patent_doc_number] => 09649339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'LAT adapter molecule for enhanced T-cell signaling and method of use' [patent_app_type] => utility [patent_app_number] => 14/329736 [patent_app_country] => US [patent_app_date] => 2014-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 22612 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14329736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822085 [patent_doc_number] => 20160168247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'HUMANIZED OR CHIMERIC CD3 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/902757 [patent_app_country] => US [patent_app_date] => 2014-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 45830 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9813028 [patent_doc_number] => 20150024973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/318366 [patent_app_country] => US [patent_app_date] => 2014-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 126 [patent_figures_cnt] => 126 [patent_no_of_words] => 9366 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14318366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9792668 [patent_doc_number] => 20150004613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => 'METHODS FOR TREATING HEMATOPOIETIC MALIGNANCIES' [patent_app_type] => utility [patent_app_number] => 14/316357 [patent_app_country] => US [patent_app_date] => 2014-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 12000 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14316357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10967006 [patent_doc_number] => 20140370038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-18 [patent_title] => 'CD4+ CD25+ T-CELLS ACTIVATED TO A SPECIFIC ANTIGEN' [patent_app_type] => utility [patent_app_number] => 14/312117 [patent_app_country] => US [patent_app_date] => 2014-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 40992 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14312117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14794441 [patent_doc_number] => 10400215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-03 [patent_title] => Adoptive transfer of CD8 [patent_app_type] => utility [patent_app_number] => 14/303385 [patent_app_country] => US [patent_app_date] => 2014-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 11163 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14303385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9930833 [patent_doc_number] => 20150079025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/303026 [patent_app_country] => US [patent_app_date] => 2014-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 26636 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14303026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919213 [patent_doc_number] => 20140322232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/292707 [patent_app_country] => US [patent_app_date] => 2014-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17309 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14292707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10032681 [patent_doc_number] => 09073987 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-07 [patent_title] => 'Methods of administering anti-TNFα antibodies' [patent_app_type] => utility [patent_app_number] => 14/292759 [patent_app_country] => US [patent_app_date] => 2014-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 17318 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14292759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10744265 [patent_doc_number] => 20160090416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'NOVEL ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/893497 [patent_app_country] => US [patent_app_date] => 2014-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 17742 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14893497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10938787 [patent_doc_number] => 20140341809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'High-Affinity DMF5 T Cell Receptor (TCR) Variants' [patent_app_type] => utility [patent_app_number] => 14/280308 [patent_app_country] => US [patent_app_date] => 2014-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15127 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14280308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916648 [patent_doc_number] => 20150071853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'NUCLEOTIDE AND PROTEIN SEQUENCES OF AN ANTIBODY DIRECTED AGAINST AN EPITOPE COMMON TO HUMAN ACIDIC AND BASIC FERRITINS, MONOCLONAL ANTIBODIES OR ANTIBODY-LIKE MOLECULES COMPRISING THESE SEQUENCES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/277106 [patent_app_country] => US [patent_app_date] => 2014-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 16643 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14277106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10905275 [patent_doc_number] => 20140308289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-16 [patent_title] => 'EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY' [patent_app_type] => utility [patent_app_number] => 14/270470 [patent_app_country] => US [patent_app_date] => 2014-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 21711 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14270470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756240 [patent_doc_number] => 20140286941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'TREATMENT OF TNFALPHA RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/268628 [patent_app_country] => US [patent_app_date] => 2014-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22505 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14268628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756237 [patent_doc_number] => 20140286939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'TREATMENT OF TNFALPHA RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/268449 [patent_app_country] => US [patent_app_date] => 2014-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22508 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14268449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9756239 [patent_doc_number] => 20140286940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-25 [patent_title] => 'TREATMENT OF TNFALPHA RELATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/268614 [patent_app_country] => US [patent_app_date] => 2014-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22507 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14268614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670452 [patent_doc_number] => 20140234315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'scFv Antibodies Which Pass Epithelial and/or Endothelial Layers' [patent_app_type] => utility [patent_app_number] => 14/266444 [patent_app_country] => US [patent_app_date] => 2014-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 19273 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14266444 [rel_patent_id] =>[rel_patent_doc_number] =>)